Loading…
← CockpitCompetitor Analysis › 603520.SS Zhejiang Starry Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Starry Pharmaceutical Co., Ltd. Class A603520.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum weak 32
Mkt cap
$491M
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$7.47M
20-day average traded
Fwd P/E
25.8×
forward earnings
ROIC−WACC
-2.2 pp
WACC 6.1%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥7.55
1D-0.4%
1W-6.7%
1M-6.8%
3M-16.2%
6M-44.3%
YTD-19.7%
1Y-28.6%
ATR %2.7%
52w lowhigh47.5% off high

What Zhejiang Starry Pharmaceutical does

Employees: 1,905

Zhejiang Starry Pharmaceutical at a glance

Size Zhejiang Starry Pharmaceutical (603520.SS) is a China Health Care company (Medical Specialties) with a market value of $491M, the 3745th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.55 on 18 Nov 2026.

Performance Over six months the shares fell 44.3%, against -17.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 9.4% over the last twelve months (peer median +5.4%); the operating margin is 2.7% (peer median 3.3%).

Valuation It trades at 25.8× forward earnings against a peer median of 19.7× (3rd most expensive of 10).

Capital Return on invested capital runs 2.2 points below its cost of capital (6.1% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 84603520.SS 58
Six months, rebased to 100: Zhejiang Starry Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Starry Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.61BCN¥2.45BCN¥2.33BCN¥2.18BCN¥2.12B
Revenue growth—+5%+7%+3%—
Gross profitCN¥660MCN¥450MCN¥385MCN¥465MCN¥449M
EBITDAn/aCN¥311MCN¥277MCN¥325MCN¥307M
Net incomeCN¥26.6MCN¥10.2M-CN¥49.1MCN¥44.2M-CN¥75.9M
Free cash flow-CN¥93.3M-CN¥266M-CN¥287M-CN¥220M-CN¥550M
Capital expenditureCN¥190MCN¥269MCN¥481MCN¥266MCN¥472M
Total debtCN¥2.82BCN¥2.97BCN¥2.68BCN¥3.19BCN¥2.99B

Quarterly statements and history in the cockpit →

Zhejiang Starry Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%MEDX002932688606688580301033688298300246CEVIANGOAVR6033097979300639NNNN300439MDXG300289468530603520.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Starry Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×MEDX688606688580301033CEVI60330979793006394549603520.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Starry Pharmaceutical is the large dot.

Zhejiang Starry Pharmaceutical competitors and peer comparison

How Zhejiang Starry Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Starry Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603520.SSPeer medianRank in peer set
1-month return-6.8%-4.6%10th lowest of 21
6-month return-44.3%-17.0%2nd lowest of 21
Distance from 52-week high-47.5%-41.7%8th lowest of 21
Revenue growth (TTM)+9.4%+5.4%6th highest of 21
Operating margin2.7%3.3%11th highest of 21
Forward P/E25.8×19.7×3rd most expensive of 10
ROIC minus cost of capital-2.2 pp-1.6 pp8th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%11.9×-5.9%+7.7%
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
MiMedx MDXGUnited States$464M-16%-23%-8%n/a10.9%+11.0%
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%n/a36.0%-6.9%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%n/an/an/a

Questions

Which companies are Zhejiang Starry Pharmaceutical's closest peers?
The cockpit's peer set: medmix (MEDX.SW), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Hangzhou Alltest Biotech (688606.SS), Nanjing Vishee Medical Technology (688580.SS), Medprin Regenerative Medical Technologies (301033.SZ), Zhejiang Orient Gene Biotech (688298.SS), Guangdong Biolight Meditech (300246.SZ), CellaVision (CEVI.ST).
Is Zhejiang Starry Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 25.8× against a peer median of 19.7×, 3rd most expensive of 10 in its peer set.
How has Zhejiang Starry Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -44.3% against -17.0% for the median peer; over one year -28.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.